BMS-986165, an Oral, Selective TYK2 Inhibitor, in the Treatment of Moderate to Severe Psoriasis as Assessed by the Static Physician's Global Assessment (sPGA)/Body Surface Area (BSA) Composite Tool (sPGAxBSA), a Clinically Useful Alternative to PASI

Main Article Content

Alice B Gottlieb
Bruce Strober
Diamant Thaçi
Kenneth Gordon
Sundeep Kundu
Renata Kisa
Lan Wei
Subhashis Banerjee
Joseph Merola


Psoriasis, Tyrosine Kinase Inhibitor


Abstract not available.


1. Spuls PI et al. J Invest Dermatol. 2010;130:933-943.

2. Walsh JA et al. J Am Acad Dermatol. 2013;69:931-937.

3. Duffin KC et al. J Drugs Dermatol. 2017;16:147-153.

4. Gottlieb AB et al. Dermatology. 2019;235:348-354.

5. Merola JF et al. J Invest Dermatol. 2018;138:1955-1961.

6. Watford WT et al. Immunol Rev. 2004;202:139-156.

7. Tokarski JS et al. J Biol Chem. 2015;290:11061-11074.

8. Volpe E et al. Nat Immunol. 2008;9:650-657.

9. Geremia A et al. J Exp Med. 2011;208:1127-1133.

10. Tucci M et al. Clin Exp Immunol. 2008;154:247-254.

11. Gillooly K et al. Arthritis Rheumatol. 2016;68(suppl10):abstract 11L.

12. Papp K et al. N Engl J Med. 2018;379:1313-1321.

13. Gottlieb AB et al. J Am Acad Dermatol. 2017;77:1178-1180.